Yi et al., 2019 - Google Patents
Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapyYi et al., 2019
View HTML- Document ID
- 6456769268961756407
- Author
- Yi S
- Zhang X
- Sangji M
- Liu Y
- Allen S
- Xiao B
- Bobbala S
- Braverman C
- Cai L
- Hecker P
- DeBerge M
- Thorp E
- Temel R
- Stupp S
- Scott E
- Publication year
- Publication venue
- Advanced functional materials
External Links
Snippet
The principle cause of cardiovascular disease (CVD) is atherosclerosis, a chronic inflammatory condition characterized by immunologically complex fatty lesions within the intima of arterial vessel walls. Dendritic cells (DCs) are key regulators of atherosclerotic …
- 229920000575 polymersome 0 title abstract description 107
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yi et al. | Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy | |
| Kugeratski et al. | Exosomes as mediators of immune regulation and immunotherapy in cancer | |
| Yaghoubi et al. | Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment | |
| Marín et al. | Tolerogenic dendritic cells in solid organ transplantation: where do we stand? | |
| Sutherland et al. | Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer | |
| Gil-Pulido et al. | Antigen-presenting dendritic cells in atherosclerosis | |
| MacRitchie et al. | Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E–deficient mice | |
| Morishita et al. | Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide | |
| Sage et al. | MHC class II–restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity | |
| Wang et al. | Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells | |
| Galea et al. | PD-L1–and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease | |
| Kottke et al. | Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer | |
| Kwon et al. | Nanoparticle‐Mediated Blocking of Excessive Inflammation for Prevention of Heart Failure Following Myocardial Infarction | |
| Kool et al. | Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs | |
| Zou et al. | HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs | |
| Xie et al. | Complement-activated interferon-γ–primed human endothelium transpresents interleukin-15 to CD8+ T cells | |
| Li et al. | Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway | |
| EP3841112A1 (en) | Extracellular vesicles targeting dendritic cells and uses thereof | |
| Curley et al. | Immunomodulation of intracranial melanoma in response to blood-tumor barrier opening with focused ultrasound | |
| JPWO2006106912A1 (en) | Cancer-related antigen analog peptide and use thereof | |
| US20190030074A1 (en) | Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound | |
| Chyu et al. | Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis | |
| US20220251200A1 (en) | Extracellular vesicles targeting t cells and uses thereof | |
| JP2014516914A (en) | Immunomodulatory compositions, methods and systems comprising immunogenic fragments of APOB100 | |
| EP2637685A1 (en) | Immunomodulatory methods and systems for treatment and/or prevention of aneurysms |